Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Rheumatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12595617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and laboratory features of scleroderma patients with pulmonary hypertension.

  2000cited by this paper
• Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.

  1998cited by this paper
• Plasma coagulation profiles in patients with severe primary pulmonary hypertension.

  1998cited by this paper
• Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.

  1997cited by this paper
• Increased tissue factor pathway inhibitor in patients with acute myocardial infarction

  1997cited by this paper
• Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

  1997cited by this paper
• Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients.

  1997cited by this paper
• Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).

  1996cited by this paper
• Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.

  1996cited by this paper
• Coagulation and fibrinolytic parameters in patients with pulmonary hypertension

  1996cited by this paper
• Sustained activation of blood coagulation in patients with cerebral thrombosis

  1995cited by this paper
• Coagulation‐Fibrinolysis System in Poststroke Patients Receiving Antiplatelet Medication

  1993cited by this paper
• Plasma thrombomodulin and alpha 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus.

  1992cited by this paper
• Clinical evaluation of scleroderma spectrum disorders using a points system

  1992cited by this paper
• Plasma anticoagulant system in patients with pulmonary hypertension.

  1990cited by this paper
• Clotting activation and impairment of fibrinolysis in malignancy.

  1989cited by this paper
• Thrombin and plasmin generation in patients with liver disease

  1989cited by this paper
• Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.

  1989cited by this paper
• Elevated plasma levels of alpha 2-plasmin inhibitor-plasmin complex in patients with rheumatic diseases. Possible role of fibrinolytic mechanism in vasculitis.

  1989cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

  1988cited by this paper
• Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.

  1987cited by this paper
• Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

  1986cited by this paper
• Pulmonary involvement in systemic sclerosis (scleroderma).

  1985cited by this paper
• Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma.

  1979cited by this paper
• The behavior of alpha2-plasmin inhibitor in fibrinolytic states.

  1977cited by this paper
• Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).

  1977cited by this paper

• Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases

  2025cites this paper
• Plasmin-Antiplasmin Complex as a New Predictive Marker of Postoperative Venous Thromboembolism in Patients with Gynecologic Malignancy

  2025cites this paper
• α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis

  2022cites this paper
• MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice

  2021cites this paper
• Alternatively activated macrophages are associated with the α2AP production that occurs with the development of dermal fibrosis

  2020cites this paper
• α2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses

  2020cites this paper
• Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia

  2020cites this paper
• The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies

  2020cites this paper
• The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis

  2019cites this paper
• Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease

  2017cites this paper
• α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis

  2017cites this paper
• The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis.

  2016cites this paper
• SnapshotDx Quiz: April 2016.

  2016cites this paper
• Alpha2-antiplasmin: A New Target for Fibrotic Diseases

  2015cites this paper
• Biomarkers for pediatric pulmonary arterial hypertension: challenges and recommendations.

  2015cites this paper
• Pathogenesis of Systemic Sclerosis

  2015cites this paper
• Predicting Perioperative Venous Thromboembolism in Japanese Gynecological Patients

  2014cites this paper
• α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction

  2014cites this paper
• Biomarkers in pulmonary hypertension: what do we know?

  2013cites this paper
• Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension

  2013cites this paper
• Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).

  2013cites this paper
• Immunopathology and Infectious Diseases 2-Antiplasmin Is Associated with the Progression of Fibrosis

  2010cites this paper
• alpha2-antiplasmin is associated with the progression of fibrosis.

  2010cites this paper
• Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis.

  2007cites this paper
• α2‐Antiplasmin is involved in the production of transforming growth factor β1 and fibrosis

  2007cites this paper
• Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry.

  2006cites this paper
• Pulmonary Involvement in Systemic Sclerosis

  2006cites this paper
• Biochemical markers in the management of pulmonary hypertension.

  2005cites this paper
• Evaluation and management of pulmonary hypertension in systemic sclerosis

  2003cites this paper